Cue Health has been awarded a $481M other transaction agreement by the Department of Defense to increase manufacturing capacity for testing kits meant to detect COVID-19 infections.
The award, which DoD issued on behalf of the Department of Health and Human Services, calls for the medical technology company to field as many as 6M point-of-care tests by March, Cue said Tuesday.
Cue’s platform is designed to identify the RNA element of the SARS-CoV-2 virus from nasal swab samples. Users may obtain test results within 20 minutes through an application, the company noted.
The Food and Drug Administration granted emergency use authorization to the firm's COVID-19 test and health monitoring system in June.
Ayub Khattak, founder and CEO of Cue, said the company envisions its product to “enable individuals to have more control over their health” by providing access to data in real time.
HHS partnered with the Pentagon's Defense Assisted Acquisition Cell and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for the contracting effort, according to a DoD notice.
